Synergistic efficacies of thymoquinone and standard antibiotics against multi-drug resistant isolates

Ayed A. Dera, PhD, Irfan Ahmad, PhD, Prasanna Rajagopalan, PhD, Mesfer Al Shahrani, PhD, Ahmed Saif, PhD, Mohammad Y. Alshahrani, PhD, Yasser Alraey, PhD, Ahmad M. Alamri, PhD, Sultan Alasmari, PhD, Mohammed Makkawi, PhD, Ali G. Alkhathami, PhD, Gaffar Zaman, MD, Abdulrahim Hakami, PhD, Razan Alhefzi, MSc, Mohammad A. Alfhili, PhD.

ABSTRACT

This study was conducted from May 2019 to March 2020 at the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Kingdom of Saudi Arabia. E-mail: ayedd@kku.edu.sa

Received 14th November 2020. Accepted 14th January 2021.

From the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha; From the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran; and the Chair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences (AlAmri), College of Applied Medical Sciences, King Khalid University, Abha; from the Department of Clinical Laboratory Sciences (Saif), College of Applied Medical Sciences, Najran University, Najran; and the Chair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences (AlAmri), College of Applied Medical Sciences, King Khalid University, Abha.

From the Department of Clinical Laboratory Sciences, Central Research Laboratory (Dera, Ahmad, Rajagopalan, Al Shahrani, Alshahrani, Alraey, Alamri, Alasmari, Makkawi, Alkhathami, Zaman, Hakami, Alhefzi), College of Applied Medical Sciences, King Khalid University, and From the Department of Clinical Laboratory Sciences, Central Research Laboratory (AlAmri), College of Applied Medical Sciences, and Cancer Research Unit, King Khalid University, Abha; from the Department of Clinical Laboratory Sciences (Saif), College of Applied Medical Sciences, Najran University, Najran; and the Chair of Medical and Molecular Genetics Research, Department of Clinical Laboratory Sciences (AlAmri), College of Applied Medical Sciences, King Khalid University, Abha.

doi: 10.15537/smj.2021.2.25706

From the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Kingdom of Saudi Arabia. E-mail: ayedd@kku.edu.sa

ORCID ID: https://orcid.org/0000-0002-6248-8983

Objective: To explore the antibacterial activity of thymoquinone (TQ), a quinone extracted from Nigella sativa.

Method: This study was conducted from May 2019 to March 2020 at the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. The antimicrobial activity, minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC) of TQ were determined using an agar well diffusion method and broth microdilution assays, and the synergistic effect was evaluated using antibiotics in parallel. The disruptive effect of TQ on bacterial cell membranes was determined using scanning electron microscopy. The antivirus properties of TQ, which include adherence and biofilm formation, were also investigated using adherence and biofilm formation assays, respectively.

Results: Thymoquinone demonstrated bactericidal efficacy against 4/14 bacterial strains, with MIC range of 1.04-8.3 μg/mL and and MBC range of 10.41-66.66 μg/mL. Thymoquinone showed synergism against Klebsiella pneumoniae, Staphylococcus epidermidis (American Type Culture Collection 12228), Staphylococcus aureus, and Staphylococcus epidermidis in combination with the tested antibiotics. Thymoquinone inhibited bacterial adhesion by 39%-54%, 48%-68%, and 61%-81% at 0.5 × MIC, 1 × MIC, and 2 × MIC, respectively. The tested bacterial strains significantly inhibited biofilm formation after treatment with various concentrations of TQ for 24 and 48 hours.

Conclusion: The combinatory effect of TQ with antimicrobials should be considered when developing new antimicrobial therapy regimens to overcome multidrug-resistant.

Keywords: thymoquinone, antibacterial, adhesion, biofilm formation, synergism
Antibiotic resistance has become a major health issue over the past decade due to the rapid growth of multidrug-resistant (MDR) microbes. Antimicrobial drugs are effective in bacterial infection control. However, microbes have the ability to develop resistance to several active antimicrobials. Due to the emergence of multidrug resistance and the insufficiency of new antimicrobials, novel and innovative approaches to combat MDR bacteria are crucial. However, bacteria efficiently develop resistance to antimicrobials soon after they have been introduced, and the majority of antibiotics have side effects. Therefore, searches for new drugs or combinations with less toxicity and uncompromised efficacy against resistant strains are continually evolving. Nonetheless, the issue of bacterial resistance to antibiotics was resolved by the uncovering of new antibiotics, like glycopeptides, aminoglycosides, and macrolides, as well as by chemically modifying existing medicines.

A potential strategy to minimize microbial resistance is the administration of antimicrobials in combination with naturally available compounds. Phytochemicals synergistically enhance the effect of traditional antimicrobials. Thymoquinone (TQ; 2-isopropyl-5-methyl-1,4-benzoquinone) is an essential active compound of *Nigella sativa* (*N. sativa*) L. seeds (black seed), which have been traditionally used for decades in the Middle East, Northern Africa, and India as a natural remedy for many contagious diseases such as bronchitis, pulmonary infection, cough, influenza, and fever. Thymoquinone exerts various pharmacological effects and has antiinflammatory, anticancer, anti-diabetic, antiasthmatic, hypolipidemic, antihypertensive, nephroprotective, and antimicrobial activities.

The antibacterial effects of TQ and other *N. sativa* extracts have been determined against *Staphylococcus aureus* (*S. aureus*), *Pseudomonas aeruginosa* (*P. aeruginosa*), *Listeria monocytogenes*, and *Escherichia coli* (*E. coli*). Thymoquinone exerts inhibitory effects against gram-negative and gram-positive bacteria. A diethyl ether extract of *N. sativa* showed synergy with streptomycin and gentamicin and an additive effect with tetracycline, streptomycin, doxycycline, tobramycin, nalidixic acid, chloramphenicol, ampicillin, co-trimoxazole, and lincomycin. Furthermore, both antibiotic-sensitive and MDR gram-positive and gram-negative bacterial isolates are susceptible to *N. sativa* extracts. This study aimed to further elucidate the potential effect of TQ against clinically significant bacteria by investigating the antibacterial effect of TQ alone and in combination with different antibiotics against drug-resistant isolates.

**Methods.** This is an experimental study which was conducted from May 2019 to March 2020 in the Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.

**Organisms and chemicals.** The antibacterial effect of TQ was examined using pathogenic strains, including the gram-negative bacteria *P. aeruginosa* (American Type Culture Collection [ATCC] 27853), *E. coli* (ATCC 25922), *E. coli, Salmonella typhi, Pseudomonas sp., Klebsiella pneumoniae* (*K. pneumoniae*), and *Shigella sp*., and the gram-positive bacteria *Enterococcus faecalis* (ATCC 29212), *S. epidermidis* (ATCC 12228), *S. aureus, S. saprophyticus, S. epidermidis, Streptococcus pyogenes*, and *Mycobacterium smegmatis*. Gentamycin, ofloxacin, tetracycline, penicillin, chloramphenicol, nalidixic acid, and TQ were purchased from Sigma (Sigma-Aldrich, Switzerland).

**Antimicrobial susceptibility assays.** The antimicrobial activity of the compounds was evaluated using an agar well diffusion method. The bacterial culture was inoculated in lysogeny broth and incubated at 37°C for 3 h (hours). The turbidity of the inoculum was consequently adjusted using phosphate-buffered saline (PBS) to be equivalent to 0.5 McFarland’s standard. Then, 20 μL of TQ (50 μg/mL) was transferred into each well of the Petri dishes, which were then incubated aerobically at 37°C for 24 hours (h). The width of the zone of inhibition of bacterial growth surrounding each well was calculated in millimeters, as previously described.

**Determination of minimum inhibitory concentration (MIC).** The MICs of TQ against the bacterial strains were determined by broth microdilution assays using TQ concentrations of 0.024-50 μg/mL. Two-fold dilutions of TQ (100 μL) were pipetted into the wells of a sterile flat-bottomed 96-well plate for each strain under test. The initial inoculum concentration for each strain was 1.5 × 10⁵ colony-forming units/mL. The control wells contained the bacterial inoculum only. The plate was incubated aerobically at 37°C for 24 h. The lowest TQ concentration that exhibited neither turbidity nor visible bacterial growth after the 24-h incubation was considered the MIC.

**Disclosure.** This study was funded by the Deanship of Scientific Research, King Khalid University, Abha, Kingdom of Saudi Arabia (Grant Number: G.R.P-3-40).
Synergistic efficacies of thymoquinone ... Dera et al

Determination of minimum bactericidal concentration (MBC). After the 24-h incubation, 100 μL of inoculum from each well of the broth microdilution assay plate was sub-cultured on Mueller–Hinton agar (MHA) plates, which were then incubated for 24 h. The minimum concentration of TQ that resulted in no bacterial growth was considered the MBC.

Synergistic antimicrobial assays. The synergistic antimicrobial activity of antibiotics (gentamycin, ofloxacin, tetracycline, penicillin, chloramphenicol, and nalidixic acid) in combination with TQ was investigated. Bacterial strains at a turbidity of 0.5 McFarland’s standard were spread on MHA plates. The specific antibiotic discs, which had been kept aerobically at 37°C for 24 h, were separately soaked in 5 μL of TQ (at the MBC value) and placed on the inoculated MHA plates. Then, the plates were incubated aerobically at 37°C for 24 h. The inhibition zones formed by TQ in combination with the selected antibiotics after overnight incubation were calculated, as previously described.24

Scanning electron microscopy (SEM). Scanning electron microscopy was used to investigate the effect of TQ on cell morphology.25 Scanning electron microscopy sample preparation was initially carried out in centrifuge tubes. Then, the bacterial specimens were instantly fixed in 2.5% (wt/vol) phosphate-buffered glutaraldehyde (pH 7.4) at 4°C for 4 h, followed by post-fixation in 1% phosphate-buffered osmium tetroxide (pH 7.4) for 1 h. After washing and dehydration in ascending grades of ethanol, critical-point drying was performed using an EMitech K850 critical-point dryer. The samples were mounted on aluminum mounts with silver glue and then sputtered with a gold coat using a BOC Edwards Scancoat sputter coater. The specimens were examined using a JSM-6390LV scanning electron microscope (Jeol Ltd., Japan).26

Adherence assay. Bacterial adherence was assessed as described elsewhere.27 Briefly, 100 μL of the bacterial cells under test (optical density at 610 nm [OD 610 nm] = 0.01) grown in Roswell Park Memorial Institute (RPMI), New York, United States in America (USA) 1640 media and buffered with 0.165 M morpholinepropanesulfonic acid (MOPS) (Sigma-Aldrich, MO, USA) at pH 7.0 were loaded into all wells of a 96-well plate. Then, the bacterial cells were treated with different concentrations of TQ (0.5 × MIC, 1 × MIC, and 2 × MIC) and incubated for 6 h at 37°C. Untreated bacterial cells were used in each set of experiments as negative controls. Following incubation, the media were discarded, and each well was rinsed twice with 200 μL PBS to eliminate the non-adherent bacterial cells. Then, 100 μL of Alamar blue at an absolute concentration of 5% in RPMI 1640 media was loaded into each well, followed by incubation at 37°C for 6 h. The amount of fluorescence was measured at 555 and 585 nm for excitation and emission, respectively, using a Synergy HT microplate reader (BioTek Instruments, VT, USA).

Biofilm formation assay. Biofilm production was assessed by the inoculating the tested bacterial cells suspensions (OD 610 nm = 0.01) grown in RPMI 1640 media buffered with 0.165 M MOPS (pH 7.0) into the wells of a sterile flat-bottomed 96-well plate, and the plate was incubated for 6 h at 37°C.28 Thereafter, the culture medium was carefully removed without disturbing the formation of biofilm. Then, different TQ concentrations (0.5 × MIC, 1 × MIC, and 2 × MIC) were prepared in fresh RPMI 1640 medium and loaded into the wells. Untreated bacterial cells were used as negative controls in each set of experiments. The 96-well plate was further incubated at 37°C, and the effect of TQ on biofilm formation was assessed after 24 h and 48 h, as previously described.29

Statistical analysis. Each investigation was conducted in triplicate, and the results were presented as means ± standard deviation (SD). GraphPad Prism software v6.0 (GraphPad, CA, USA) was used to perform the statistical analyses. One-way analysis of variance with Dunnett’s multiple comparison test was used to compare the mean between different groups with that of the control. P-values < 0.05 were considered statistically significant.

Results. Antibacterial activity of TQ. Thymoquinone exerted a bactericidal effect on 4/14 strains, with MICs of 1.04-8.3 μg/mL and MBCs of 10.41-66.66 μg/mL (Table 1 & Figure 1). This effect was almost indistinguishable from the tested antibiotics (ofloxacin, gentamycin, tetracycline, penicillin, chloramphenicol, and nalidixic acid). The gram-negative bacteria E. coli ATCC 25922, P. aeruginosa ATCC 27853, Pseudomonas sp., Salmonella typhi, Shigella sp., and E. coli were resistant to TQ. However, for gram-positive bacteria, only Enterococcus faecalis ATCC 29212, M. smegmatis, S. saprophyticus, and S. pyogenes appeared resistant to TQ.

Synergism action. For gram-positive bacteria, TQ showed synergism in combination with gentamicin and penicillin against S. epidermidis ATCC 12228; with ofloxacin, tetracycline, and chloramphenicol against S. aureus; and with ofloxacin and penicillin against S. epidermidis. For gram-negative bacteria, TQ showed synergism with gentamicin, ofloxacin, penicillin, and nalidixic acid against K. pneumoniae (Table 2).

Antagonism action. For gram-positive bacteria, TQ showed antagonism against S. epidermidis ATCC...
Synergistic efficacies of thymoquinone ... Dera et al

Table 1 - Antibacterial activity of thymoquinone against pathogenic bacterial strains.

| Organism                     | Origin      | Zone of inhibition (50 μg/ml) mm | Thymoquinone Mean (SD) μg/ml | MIC Mean (SD) μg/ml | MBC Mean (SD) μg/ml |
|------------------------------|-------------|----------------------------------|------------------------------|--------------------|--------------------|
| **Gram negative bacteria**   |             |                                  |                              |                    |                    |
| Pseudomonas aeruginosa (ATCC 27853) | ATCC        | -                                | -                            | -                  | -                  |
| Escherichia coli (ATCC 25922) | ATCC        | -                                | -                            | -                  | -                  |
| Pseudomonas                  |             |                                  |                              |                    |                    |
| Salmonella typhi             | Clinical    | 15 (2)                           | 1.30 (0.45)                  | 33.33 (14.43)      |                    |
| Klebsiella pneumoniae        | Clinical    | -                                | -                            | -                  | -                  |
| Shigella                     | Clinical    | -                                | -                            | -                  | -                  |
| Escherichia coli             | Clinical    | -                                | -                            | -                  | -                  |
| **Gram positive bacteria**   |             |                                  |                              |                    |                    |
| Enterococcus faecalis (ATCC 29212) | ATCC        | 17 (1.73)                        | 1.04 (0.45)                  | 10.41 (3.60)       |                    |
| Staphylococcus epidermidis (ATCC 12228) | ATCC        | 15 (1)                           | 2.60 (0.90)                  | 41 (14.43)         |                    |
| Mycobacterium smegmatis      | Clinical    | 13 (1.73)                        | 8.3 (3.60)                   | 66.66 (28.86)      |                    |
| Staphylococcus aureus        | Clinical    | 15 (2)                           | 1.30 (0.45)                  | 33.33 (14.43)      |                    |
| Staphylococcus saprophyticus | Clinical    | -                                | -                            | -                  | -                  |
| Staphylococcus epidermidis   | Clinical    | -                                | -                            | -                  | -                  |
| Streptococcus pyogenes       | Clinical    | -                                | -                            | -                  | -                  |

- : no effect, MIC: minimum inhibitory concentration, MBC: minimum bactericidal concentration, ATCC: American Type Culture Collection

For gram-negative bacteria, TQ showed additive action with tetracycline and chloramphenicol against *K. pneumoniae*. Most of the results are same during each trial and there were no any significant difference observed with $\alpha=0.05$.

**Disruption of bacterial cells visualized by SEM.** Scanning electron microscopy was used to observed changes in the structural morphology of *S. epidermidis* in response to TQ (Figure 2). In the absence of TQ (control), the cells showed characteristic normal morphology (Figure 2A). Unlike the control, the cells that were treated with TQ had damaged cell membranes, showing that TQ treatment reduced the synthesis of extracellular polysaccharides (Figure 2B).

**Thymoquinone inhibits bacterial adhesion.** Adhesion assays were performed using Alamar blue dye to assess the effect of TQ on bacterial adherence. The bacterial cells showed inconsistent inhibition of adherence following exposure to various TQ concentrations, and this was concentration-dependent. For *K. pneumoniae*, *S. epidermidis* (ATCC 12228), *S. aureus*, and *S. epidermidis*, TQ inhibited bacterial adhesion by 39%-54% at 0.5 × MIC, 48%-68% at 1 × MIC, and 61%-81% at 2 × MIC (Figure 3), indicating that TQ was extremely efficient in diminishing adhesion of the tested bacteria, even at subinhibitory concentrations.

12228 when combined with ofloxacin, tetracycline, and chloramphenicol; *S. aureus* with penicillin; and *S. epidermidis* with tetracycline and chloramphenicol. However, for gram-negative bacteria, TQ antagonism was not detected against *K. pneumoniae* in combination with any of the tested antibiotics (Table 2).

**Additive action.** For gram-positive bacteria, TQ showed additive action with nalidixic acid against *S. epidermidis* ATCC 12228 and with gentamicin and nalidixic acid against *S. aureus* and *S. epidermidis*. For gram-negative bacteria, TQ showed additive action with tetracycline and chloramphenicol against *K. pneumoniae*. Most of the results are same during each trial and there were no any significant difference observed with $\alpha=0.05$.

---

Figure 1 - Antibacterial activity of TQ. A) Antibacterial activity of thymoquinone (TQ) against *Klebsiella pneumoniae*. B) Antibacterial activity of TQ against *Staphylococcus epidermidis* (ATCC 12228).
Table 2 - Synergistic antimicrobial activity of thymoquinone (TQ) with different antimicrobial agents.

| Bacteria                          | Antimicrobial agent | Mean of inhibition zone with antibiotics (mm) Mean (SD) | Mean of inhibition zone with Tq (mm) Mean (SD) | Inhibition zone with synergism Mean (SD) | Outcome | P-value |
|-----------------------------------|---------------------|--------------------------------------------------------|-----------------------------------------------|------------------------------------------|---------|---------|
| *Klebsiella pneumoniae*           | Gentamicin          | 20 (1.73)                                              | 15 (2)                                        | 37 (3.60)                               | Synergism | 0.458   |
| | Ofloxacin                     | 17 (1.0)            | 34 (1.73)                                              | Synergism                                    | 0.638                                   |         |         |
| | Tetracycline                  | 0                   | 15 (1)                                                 | Additive                                      | ≤ 0.001                                 |         |         |
| | Penicillin                    | 15 (2)              | 34 (2)                                                 | Synergism                                    | 0.485                                   |         |         |
| | Chloramphenicol                | 0                   | 15 (1.73)                                              | Additive                                      | ≤ 0.001                                 |         |         |
| | Nalidixic acid                | 3 (1)               | 20 (1)                                                 | Synergism                                    | ≤ 0.001                                 |         |         |
| *Staphylococcus epidermidis* (ATCC 12228) | Gentamicin          | 18 (2)                                                 | 36 (1)                                        | Synergism                               | 0.254   |         |
| | Ofloxacin                     | 25 (3)              | 34 (2)                                                 | Antagonism                                   | 1.258                                   |         |         |
| | Tetracycline                  | 0                   | 17 (1.73)                                              | Antagonism                                    | 0.458                                   |         |         |
| | Penicillin                    | 18 (1.73)           | 37 (3.6)                                               | Synergism                                    | 0.471                                   |         |         |
| | Chloramphenicol                | 25 (1)              | 36 (1)                                                 | Antagonism                                   | 0.689                                   |         |         |
| | Nalidixic acid                | 0                   | 17 (2.64)                                              | Additive                                      | ≤ 0.001                                 |         |         |
| *Staphylococcus aureus*          | Gentamicin          | 18 (1.73)                                              | 30 (1.73)                                    | Synergism                               | 0.356   |         |
| | Ofloxacin                     | 13 (01)             | 30 (1.73)                                              | Synergism                                    | 0.356                                   |         |         |
| | Tetracycline                  | 4 (2)               | 15 (1)                                                 | Synergism                                    | 0.095                                   |         |         |
| | Penicillin                    | 16 (1.73)           | 27 (1.73)                                              | Antagonism                                   | 0.245                                   |         |         |
| | Chloramphenicol                | 18 (2)              | 35 (2)                                                 | Synergism                                    | 0.325                                   |         |         |
| | Nalidixic acid                | 2 (1)               | 17 (1)                                                 | Additive                                      | ≤ 0.001                                 |         |         |
| *Staphylococcus epidermidis*      | Gentamicin          | 18 (1.73)                                              | 31 (3.6)                                      | Additive                               | 0.471   |         |
| | Ofloxacin                     | 17 (2.64)           | 32 (2)                                                 | Synergism                                    | 0.247                                   |         |         |
| | Tetracycline                  | 18 (1)              | 29 (1)                                                 | Antagonism                                   | 1.784                                   |         |         |
| | Penicillin                    | 3 (1)               | 21 (1)                                                 | Synergism                                    | ≤ 0.001                                 |         |         |
| | Chloramphenicol                | 20 (2)              | 26 (1.73)                                              | Antagonism                                   | 0.478                                   |         |         |
| | Nalidixic acid                | 0                   | 13 (2.64)                                              | Additive                                      | ≤ 0.001                                 |         |         |

Figure 2 - Effect of thymoquinone (TQ) on cell morphology of *Staphylococcus epidermidis*. Changes in the cellular morphology were observed by scanning electron microscopy. A) Control cell B) shows bacterial cell treated with TQ.
**Thymoquinone inhibits bacterial biofilm formation.** TQ treatment at $0.5 \times \text{MIC}$, $1 \times \text{MIC}$, and $2 \times \text{MIC}$ significantly inhibited biofilm formation in *K. pneumoniae*, *S. epidermidis* (ATCC 12228), *S. aureus*, and *S. epidermidis* by 31%-45%, 41%-59%, and 58%-81%, respectively, after 24 h and by 21%-34%, 30%-51%, and 44%-67%, respectively, after 48 h (Figure 4). The rate of biofilm formation inhibition by TQ was concentration- and time-dependent.

**Discussion.** Thymoquinone is one of the most bioactive components of *N. sativa* and has diverse beneficial properties. Regarding antimicrobial effects, TQ has a broad-spectrum efficacy encompassing gram-negative and gram-positive bacteria.\(^{27}\) Thymoquinone also exhibits a synergistic effect with gentamicin and streptomycin and an additive effect with spectinomycin, doxycycline, tobramycin, erythromycin, chloramphenicol, ampicillin, lincomycin, nalidixic acid, and a combination of sulfamethoxazole and trimethoprim.\(^{21,27}\) In our study, TQ exhibited synergism in combination with gentamicin ($p=0.254$) and penicillin ($p=0.471$) against gram-positive *S. epidermidis* (ATCC 12228). Other studies have reported a similar effect.
against *S. epidermidis* in combination with ofloxacin and penicillin. Furthermore, *S. epidermidis* strains were reported as resistant to more than one antibiotic, and *S. epidermidis* isolates were also more sensitive to ofloxacin and gentamycin. Combined with antibiotics, these natural extracts showed significant synergy, and the maximum synergistic effect was detected with cephalxin and erythromycin.\(^{30,32}\)

Methicillin-resistant *S. aureus* is the most common pathogen encountered in clinical and laboratory settings.\(^{27}\) Previous studies have suggested that TQ in combination with antibiotics, such as cephalxin, ampicillin, tetracycline, gentamicin, and chloramphenicol, may show synergistic activity against *S. aureus*.\(^{23}\) Our observations agreed with the literature, as TQ showed a synergistic effect with ofloxacin, tetracycline, and chloramphenicol against *S. aureus*.\(^{7,27}\)

Furthermore, our observations are supported by a report on TQ increasing the anti-staphylococcal effect of penicillin, tetracycline, and oxacillin against resistant bacterial strains.\(^{33}\)

The MIC values that we observed for TQ against *K. pneumoniae* were much higher than those in wild-type *E. coli*. Therefore, it is evident that *K. pneumoniae* is highly resistant to several antimicrobial agents. Multidrug-resistant efflux pumps are the most important mechanisms through which bacteria can resist antibiotics, most notably tetracyclines.\(^{34}\) This pump expels multiple drugs and could play a role in multidrug resistance.\(^{34}\) To the best of our knowledge, there is a lack of literature on TQ synergistic studies with antibiotics against *K. pneumoniae*. In our study, TQ was synergistic with gentamicin (*p* = 0.458), ofloxacin (*p* = 0.638), penicillin (*p* = 0.485), and nalidixic acid (*p* ≤ 0.001) against gram-negative *K. pneumoniae*. Thymoquine has been reported to exert antibacterial activity against both gram-positive and gram-negative bacteria. Furthermore, MDR clinical strains of *Shigella flexneri*, *S. typhimurium*, *S. aureus*, and *S. enteritidis* were reported with TQ sensitivity similar to that of non-MDR strains, and the susceptibility of resistant bacterial isolates to TQ has been reported.\(^{35}\)

Clinical isolates of *S. aureus* are often resistant to nearly all of the frequently used antimicrobials, including macrolides, aminoglycosides, chloramphenicol, fluoroquinolones, and tetracycline.\(^{36}\) Our study demonstrated that TQ exerts synergistic lethal effects against both gram-negative and gram-positive bacteria when combined with antibiotics. Therefore, TQ could be used as an antibacterial drug.

Efflux pumps are a bacterial defense mechanism that eliminates antibiotics from the cell. The action of the efflux pumps often predisposes the progression of microorganisms toward being highly resistant to antimicrobials.\(^{37,38}\) Some investigations have demonstrated the vital function of phytochemistry to explore the effectiveness of efflux pump inhibitors, particularly against gram-positive bacteria such as *S. epidermidis* and *S. aureus*.\(^{30}\) It was also reported that TQ could inhibit efflux pumps, consequently enhancing the concentration of 4, 6-diamidino-2-phenylindole in the cells.\(^{38}\) Hence, we hypothesize that this potential mechanism could also play a role in the anti-staphylococcal activity of TQ-tetracycline in combination with antibiotics, which is consistent with our study results. In contrast, -lactams are generally responsible for staphylococcal resistance by producing modified penicillin-binding proteins (PBPs) with decreased binding properties to antimicrobial agents.\(^{39}\) Therefore, it has been suggested that TQ may play a role in inhibiting PBPs responsible for staphylococcal resistance.\(^{34}\) Previous findings demonstrated that TQ could be an effective compound in combination with other antimicrobials against many bacterial strains, especially *Staphylococcus* sp. However, further investigations are necessary to examine their practical application.\(^{40}\)

The capability of bacteria to adhere and form biofilm is responsible for their virulence. Our study revealed that TQ inhibited bacterial adhesion and biofilm formation. Adhesion properties are directly related to biofilm formation and lead to plaque formation. Bacterial cells have specialized proteins (adhesins) that encode host cell surface glycoproteins, enabling bacteria to adhere to host cells.\(^{41}\) We found that TQ significantly inhibited adherence by 39%-81% in a dose-dependent manner in *K. pneumoniae*, *S. epidermidis* (ATCC 12228), *S. aureus*, and *S. epidermidis*, and adherence to host tissue lead to biofilm formation in these strains. Biofilm is a vital virulence factor in periodontal bacteria. It enhances resistance to most conventional antibacterial drugs.\(^{42}\) Furthermore, there are numerous reports that biofilms are more resistant than planktonic cells to existing antimicrobials.\(^{43}\) In our study, TQ treatment significantly suppressed biofilm formation in a concentration-dependent manner by 31%-81% for 24 h and 21%-67% for 48 h. Our findings support the assumption that TQ targets membrane adhesion proteins to inhibit adherence to host cells, subsequently inhibiting biofilm formation.

In conclusion, our study demonstrates that TQ can enhance the antibacterial activity of some antimicrobials. As demonstrated in Table 1, TQ was found more efficient anti-bacterial activities particularly...
against gram-positive bacteria. Although our findings provide new insights into possible mechanistic scenarios associated with the combinatory effect of TQ with antimicrobials. Further investigations are necessary to facilitate the development of novel therapeutic strategies using TQ against resistant microbes.

**Acknowledgment.** The authors are thankful to the Deanship of Scientific Research, King Khalid University, Abha, Kingdom of Saudi Arabia, for financially supporting this work through the General Research Project under (grant number G.R.P-3-40). The authors also thank the Deanship of Scientific Research and Researcher’s Services & Support Unit, King Saud University, Riyadh, Kingdom of Saudi Arabia for their technical support. The authors also acknowledge Enago (www.enago.com) for English language editing.

**References**

1. Abdallah EM. Black seed (*Nigella sativa*) as antimicrobial drug: a mini-Review. *Noor Appro Drug Des Dev* 2017; 3: 555603.
2. Gold HS, Moellerling RC. Antimicrobial-drug resistance. *N Engl J Med* 1996; 335: 1445-1453.
3. Bajera T, Silha D, Ventura K, Bajerov P. Composition and antimicrobial activity of the essential oil, distilled aromatic water and herbal infusion from *Epilobium parviflorum* Schreb. *Ind Crops Prod* 2017; 100: 95-105.
4. Sonam C, Sharma K, Guleria S. Antimicrobial activity of some essential oils - present status and future perspectives. *Medicines (Basel)* 2017; 4: 58.
5. Okeke IN, Lasminarayan R, Bhutta ZA, Duse A, Jenkins P, O’Brien T, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. *Lancet Infect Dis* 2005; 5: 481-493.
6. Neu HC. The crisis in antibiotic resistance. *Science* 1992; 257: 1064-1073.
7. Eman H. Antibacterial activity of thymoquinone and thymohydroquinone of *Nigella sativa* L. and their interaction with some antibiotics. *Adv Biol Res* 2009; 3: 148-152.
8. Drago L, De Vecchi E, Nicola L. In vitro evaluation of antibiotics’ combinations for empirical therapy of suspected methicillin resistant *Staphylococcus aureus* severe respiratory infections. *BMJ Infect Dis* 2007; 7: 111.
9. HemaIswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious diseases. *PhytoMedicine* 2008; 15: 639-652.
10. Mouwakhe A, Telbys A, Spengler G, Mohácsi-Farkas C, Kiskó G. Antibacterial and resistance modifying activities of *Nigella sativa* essential oil and its active compounds against Listeria monocytogenes. *In Vivo* 2018; 32; 737-743.
11. Kokoska L. Chemistry and biological activity of Nigella genus: the antimicrobial and anti-inflammatory effects of seed extracts, essential oils and compounds of six Nigella species. Germany: LAP LAMBERT Academic Publishing; 2011.
12. Randhawa MA, Alenazy AK, Alrowaili MG, Basha J. An active principle of *Nigella sativa* L., thymoquinone, showing significant antimicrobial activity against anaerobic bacteria. *J Intercult Ethnopharmacol* 2017; 6: 97-101.
13. El-Fatatry HM. Isolation and structure assignment of an antimicrobial principle from the volatile oil of *Nigella sativa* L seeds. *Pharmazie* 1975; 30; 109-111.
14. Dera AA, Rajagopalan P, Alfhili MA, Ahmed I, Chandramoorthy HC. Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats. *BioFactors* 2019; 46: 292-300.
15. Dera A, Rajagopalan P, Ahmed I, Alfhili M, Alsughayyir J, Chandramoorthy HC. Thymoquinone attenuates IgE-mediated allergic response via pi3k-Akt-NFκB pathway and upregulation of the Nrf2-HO1 axis. *J Food Biochem* 2020; 44: e13216.
16. Dera AA, Rajagopalan P, Al Fayi M, Ahmed I, Chandramoorthy HC. Indirubin-3-monoxide and thymoquinone exhibit synergistic efficacy as therapeutic combination in in-vitro and in-vivo models of lung cancer. *Arch. Pharm Res* 2020; 43: 655-665.
17. Asaduzzaman K, Tania M, Shangyi FU, Junjiang FU. (2017) Thymoquinone, as an anticancer molecule; from basic research to clinical investigation. *Oncotarget* 2017; 8: 51907-51919.
18. Bakathir HA, Abbas NA. Detection of the Antibacterial Effect of Nigella Sativa Ground Seeds with Water. *Afr J Tradit Complement Altern Med* 2011; 8: 159-164.
19. Randhawa MA, Alenazy AK, Alrowaili MG, Basha J. An active principle of *Nigella sativa* L., thymoquinone, showing significant antimicrobial activity against anaerobic bacteria. *J Intercult Ethnopharmacol* 2017; 6: 97-101.
20. El-Fatatry HM. Isolation and structure assignment of an antimicrobial principle from the volatile oil of *Nigella sativa* L seeds. *Pharmazie* 1975; 30: 109-111.
21. Hanafi MS, Hatem ME. Studies on the anti-microbial activity of the *Nigella sativa* seed (Black Cumin). *J Ethnopharmacol* 1991; 34: 275-278.
22. Morsi NM. Antimicrobial effect of crude extracts of *Nigella sativa* on multiple antibiotic resistant bacteria. *Acta Microbiologica Polonica* 2000; 49: 63-74.
23. Goyal SN, Prajapati CP, Gore PR, Patil CR, Mahajan UB, Sharma C. Therapeutic potential and pharmaceutical development of thymoquinone: a multitargeted molecule of natural origin. *Front Pharmacol* 2017; 8: 656.
24. Nussdorfer P, Cilenkic I, Zorn B, Petrovic D. Adapted methods for scanning electron microscopy (SEM) in assessment of human sperm morphology. *Bosn J Basic Med Sci* 2018; 18: 43-48.
25. Eid RA, Alkhateeb MA, Al-Shraim M, Eleawa SM, Shatoor AS, Al-Fattary HM. Isolation and structure assignment of an antimicrobial principle from the volatile oil of *Nigella sativa* L seeds. *Pharmazie* 1975; 30: 109-111.
26. Saqib SA, Al Qahtani NA, Ahmad I, Al Shahrani SS, Asiri EA. Evaluation and comparison of antibacterial efficacy of herbal extracts in combination with antibiotics on periodontal pathogens: an in vitro microbiological study. *Antibiotics* 2019; 8: 89.
27. Forouzanfar F, Fazly Bazzaz BS, Hosseinzadeh H. Black cumin seed (*Nigella sativa*): a mini-Review. *Adv Biol Res* 2018; 32: 737-743.
28. Randhawa MA, Alenazy AK, Alrowaili MG, Basha J. An active principle of *Nigella sativa* L., thymoquinone, showing significant antimicrobial activity against anaerobic bacteria. *J Intercult Ethnopharmacol* 2017; 6: 97-101.
29. Jin Y, Samaranayake LP, Samaranayake Y, Yip HK. Biofilm formation of Candida albicans is variably affected by saliva and water and herbal infusion from *Epilobium parviflorum* Schreb. *Arch Oral Biol* 2004; 49: 789-798.
30. Abidi SH, Ahmed K, Sherwani SK, Kazmi SU. Synergy between antibiotics and natural agents results in increased anti-bacterial activity against Staphylococcus epidermidis. *J Infect Dev Countr* 2015; 9: 925-929.

31. Dodou HV, de Morais Batista AH, Sales GWP, de Medeiros SC, Rodrigues ML, Nogueira PCN, et al. Violacein antimicrobial activity on Staphylococcus epidermidis and synergistic effect on commercially available antibiotics. *J Appl Microbiol* 2017; 123: 853-860.

32. Kiari FZ, Meddah B, Meddah AT. (In vitro study on the activity of essential oil and methanolic extract from Algerian *Nigella sativa* L. Seeds on the growth kinetics of micro-organisms isolated from the buccal cavities of periodontal patients. *Saudi Dent J* 2018; 30: 312-323.

33. Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin Microbial Rev* 2006; 19: 382-382.

34. Johana R, Pavel N, Urban J, Kokoska L. Determination of anti-staphylococcal activity of thymoquinone in combinations with antibiotics by checkerboard method using EVA capmat as a vapor barrier. *Arab J Chem* 2017; 10: 566-572.

35. Ogawa W, Li DW, Ping YU, Begum A, Mizushima T, Kuroda T. Multidrug resistance in Klebsiella pneumoniae MGH78578 and cloning of genes responsible for the resistance. *Biol Pharm Bull* 2005; 28: 1505-1508.

36. Salman MT, Khan RA, Shukla J. Antimicrobial activity of *Nigella sativa* Linn. seed oil against multi-drug resistant bacteria from clinical isolates. *Nat Prod Radiance* 2008; 7: 10-14.

37. Mandell G, Douglas J, Bennett R. (1995) Principles and practices of infectious diseases, 4th ed. Edinburgh (UK): Churchill Livingstone; 1995. p. 80-112.

38. Handzlik J, Matys A, Kiec-Kononowicz K. Recent advances in multi-drug resistance (MDR) efflux pump inhibitors of Gram-positive bacteria *S. aureus*. *Antibiotics (Basel)* 2013; 2: 28-45.

39. Kouidhi B., Zmantar T., Jrah H., Souiden Y., Chaieb K., Mahdouani K. Antibacterial and resistance modifying activities of thymoquinone against oral pathogens. *Ann Clin Microbiol Antimicrob* 2011; 10: 29.

40. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. *FEMS Microbiol Rev* 2006; 30: 673-691.

41. Steinberg D. Studying plaque biofilms on various dental surfaces. In: An YH, Friedman RJ, editors. Handbook of bacterial adhesion: principles, methods, and applications. Totowa (NJ): Humana Press; 2000. p. 353-370.

42. Cazzaniga G, Ottobelli M, Ionescu A, Garcia-Godoy F, Brambilla E. Surface properties of resin-based composite materials and biofilm formation: a review of the current literature. *Am J Dent* 2015; 28: 311-320.

43. Marsh PD. Dental plaque as a biofilm and a microbial community-implications for health and disease. *BMC Oral Health*. 2006; 6: S14.